Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Expert Rev Vaccines ; 18(9): 951-968, 2019 09.
Article in English | MEDLINE | ID: mdl-31487213

ABSTRACT

Introduction: The development of more efficacious vaccines, especially subunit vaccines administered via non-invasive routes, is a priority in vaccinology. Nanogels are materials that can meet the requirements to serve as efficient vaccine delivery vehicles (in terms of thermo-sensitivity, biocompatibility, and pH-responsiveness; among others); thus there is a growing interest in exploring the potential of nanogels for vaccine development. Areas covered: Herein, a critical analysis of nanogel synthesis methodologies is presented and nanogel-based vaccines under development are summarized and placed in perspective. Promising vaccine candidates based on nanogels have been reported for cancer, obesity, and infectious diseases (mainly respiratory diseases). Some of the candidates were administered by mucosal routes which are highly attractive in terms of simple administration and induction of protective responses at both mucosal and systemic levels. Expert opinion: The most advanced models of nanogel-based vaccines comprise candidates against cancer, based on cholesteryl pullulan nanogels evaluated in clinical trials with promising findings; as well as some vaccines against respiratory pathogens tested in mice thus far. Nonetheless, the challenge for this field is advancing in clinical trials and proving the protective potential in test animals for many other candidates. Implementing green synthesis approaches for nanogels is also required.


Subject(s)
Drug Delivery Systems/methods , Nanogels/chemistry , Nanoparticles/chemistry , Vaccines/immunology , Animals , Drug Carriers , Drug Development , Glucans , Humans , Mice , Neoplasms
2.
Vaccine ; 33(31): 3650-8, 2015 Jul 17.
Article in English | MEDLINE | ID: mdl-26073010

ABSTRACT

Chikungunya virus is an emerging pathogen initially found in East Africa and currently spread into the Indian Ocean Islands, many regions of South East Asia, and in the Americas. No licensed vaccines against this eminent pathogen are available and thus intensive research in this field is a priority. This review presents the current scenario on the developments of Chikungunya virus vaccines and identifies the use of genetic engineered plants to develop attractive vaccines. The possible avenues to develop plant-made vaccines with distinct antigenic designs and expression modalities are identified and discussed considering current trends in the field.


Subject(s)
Chikungunya Fever/prevention & control , Chikungunya virus/immunology , Viral Vaccines/immunology , Africa/epidemiology , Americas/epidemiology , Asia, Southeastern/epidemiology , Chikungunya Fever/epidemiology , Drug Discovery/trends , Humans , Indian Ocean Islands/epidemiology , Plants, Genetically Modified , Vaccines, Edible/immunology , Vaccines, Edible/isolation & purification , Vaccines, Synthetic/immunology , Vaccines, Synthetic/isolation & purification , Vaccines, Virus-Like Particle/immunology , Vaccines, Virus-Like Particle/isolation & purification , Viral Vaccines/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL